CXCR1/2 Dual-Inhibitor Ladarixin Reduces Tumour Burden and Promotes Immunotherapy Response in Pancreatic Cancer

A set of preclinical models was obtained by engrafting mouse PDAC-derived cells into syngeneic immune-competent mice, as well as by orthotopically transplanting patient-derived PDAC tumour into human immune-system-reconstituted mice.
[British Journal of Cancer]

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News